These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
323 related articles for article (PubMed ID: 31754796)
1. Evaluation of [ Yadav D; Ballal S; Yadav MP; Tripathi M; Roesch F; Bal C Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):860-869. PubMed ID: 31754796 [TBL] [Abstract][Full Text] [Related]
2. Clinical evaluation of [ Gaertner FC; Plum T; Kreppel B; Eppard E; Meisenheimer M; Strunk H; Bundschuh RA; Sinnes JP; Rösch F; Essler M Nucl Med Biol; 2019; 76-77():1-9. PubMed ID: 31520872 [TBL] [Abstract][Full Text] [Related]
3. Somatostatin receptor PET in neuroendocrine tumours: 68Ga-DOTA0,Tyr3-octreotide versus 68Ga-DOTA0-lanreotide. Putzer D; Kroiss A; Waitz D; Gabriel M; Traub-Weidinger T; Uprimny C; von Guggenberg E; Decristoforo C; Warwitz B; Widmann G; Virgolini IJ Eur J Nucl Med Mol Imaging; 2013 Feb; 40(3):364-72. PubMed ID: 23151915 [TBL] [Abstract][Full Text] [Related]
4. Vertebral metastases from neuroendocrine tumours: How to avoid false positives on Gauthé M; Testart Dardel N; Ruiz Santiago F; Ohnona J; Nataf V; Montravers F; Talbot JN Eur Radiol; 2018 Sep; 28(9):3943-3952. PubMed ID: 29532242 [TBL] [Abstract][Full Text] [Related]
5. 68Ga-DOTA-TOC uptake in neuroendocrine tumour and healthy tissue: differentiation of physiological uptake and pathological processes in PET/CT. Kroiss A; Putzer D; Decristoforo C; Uprimny C; Warwitz B; Nilica B; Gabriel M; Kendler D; Waitz D; Widmann G; Virgolini IJ Eur J Nucl Med Mol Imaging; 2013 Apr; 40(4):514-23. PubMed ID: 23291643 [TBL] [Abstract][Full Text] [Related]
6. Direct comparison of (68)Ga-DOTA-TOC and (18)F-FDG PET/CT in the follow-up of patients with neuroendocrine tumour treated with the first full peptide receptor radionuclide therapy cycle. Nilica B; Waitz D; Stevanovic V; Uprimny C; Kendler D; Buxbaum S; Warwitz B; Gerardo L; Henninger B; Virgolini I; Rodrigues M Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1585-92. PubMed ID: 26922350 [TBL] [Abstract][Full Text] [Related]
7. Biodistribution and first clinical results of Ilhan H; Lindner S; Todica A; Cyran CC; Tiling R; Auernhammer CJ; Spitzweg C; Boeck S; Unterrainer M; Gildehaus FJ; Böning G; Jurkschat K; Wängler C; Wängler B; Schirrmacher R; Bartenstein P Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):870-880. PubMed ID: 31492994 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of unusual neuroendocrine tumours by means of 68Ga-DOTA-NOC PET. Fanti S; Ambrosini V; Tomassetti P; Castellucci P; Montini G; Allegri V; Grassetto G; Rubello D; Nanni C; Franchi R Biomed Pharmacother; 2008 Dec; 62(10):667-71. PubMed ID: 18358680 [TBL] [Abstract][Full Text] [Related]
17. Added value of [ Yoo J; Kim SH; Jeon SK; Bae JS; Han JK Eur Radiol; 2021 Oct; 31(10):7734-7745. PubMed ID: 33787974 [TBL] [Abstract][Full Text] [Related]
18. A prospective head-to-head comparison of Jiang Y; Liu Q; Wang G; Sui H; Wang R; Wang J; Zhu Z Eur J Nucl Med Mol Imaging; 2022 Oct; 49(12):4218-4227. PubMed ID: 35657429 [TBL] [Abstract][Full Text] [Related]
19. Tumour-to-liver ratio determined by [ Kim YI; Yoo C; Oh SJ; Lee SJ; Kang J; Hwang HS; Hong SM; Ryoo BY; Ryu JS EJNMMI Res; 2020 Jun; 10(1):63. PubMed ID: 32542576 [TBL] [Abstract][Full Text] [Related]
20. Gallium-68-DOTA-NOC PET/CT of patients with gastroenteropancreatic neuroendocrine tumors: a prospective single-center study. Naswa N; Sharma P; Kumar A; Nazar AH; Kumar R; Chumber S; Bal C AJR Am J Roentgenol; 2011 Nov; 197(5):1221-8. PubMed ID: 22021518 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]